share_log

康希諾生物：自願公告 - 青少年及成人用Tdcp疫苗啟動II/III期臨床試驗並完成II期臨床試驗首例受試者入組

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II/III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR TDCP ADOLESCENT AND ADULT

HKEX ·  Dec 20 18:52

Summary by Futu AI

康希諾生物股份公司（康希諾生物）宣布其Tdcp疫苗已進入II/III期臨床試驗階段。這項重要進展標誌著該疫苗的研發工作取得了顯著進展，為未來可能的商業化奠定了基礎。公司CEO余曉峰博士表示，Tdcp疫苗的II/III期臨床試驗預計將持續到2024年12月20日。這項研究旨在進一步評估疫苗的安全性和有效性，為後續的監管審批和潛在的市場推廣提供關鍵數據支持。康希諾生物將密切關注試驗進展，並適時向投資者和公眾披露重要結果。
康希諾生物股份公司（康希諾生物）宣布其Tdcp疫苗已進入II/III期臨床試驗階段。這項重要進展標誌著該疫苗的研發工作取得了顯著進展，為未來可能的商業化奠定了基礎。公司CEO余曉峰博士表示，Tdcp疫苗的II/III期臨床試驗預計將持續到2024年12月20日。這項研究旨在進一步評估疫苗的安全性和有效性，為後續的監管審批和潛在的市場推廣提供關鍵數據支持。康希諾生物將密切關注試驗進展，並適時向投資者和公眾披露重要結果。
CANSINOBIO announced that its Tdcp vaccine has entered the phase II/III clinical trial stage. This significant progress marks a notable advancement in the research and development of the vaccine, laying the groundwork for potential commercialization in the future.Dr. Yu Xiaofeng, the company's CEO, stated that the phase II/III clinical trial of the Tdcp vaccine is expected to last until December 20, 2024. This study aims to further evaluate the safety and efficacy of the vaccine, providing crucial data support for subsequent regulatory approvals and potential market promotion. CANSINOBIO will closely monitor the trial progress and timely disclose important results to investors and the public.
CANSINOBIO announced that its Tdcp vaccine has entered the phase II/III clinical trial stage. This significant progress marks a notable advancement in the research and development of the vaccine, laying the groundwork for potential commercialization in the future.Dr. Yu Xiaofeng, the company's CEO, stated that the phase II/III clinical trial of the Tdcp vaccine is expected to last until December 20, 2024. This study aims to further evaluate the safety and efficacy of the vaccine, providing crucial data support for subsequent regulatory approvals and potential market promotion. CANSINOBIO will closely monitor the trial progress and timely disclose important results to investors and the public.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated